Results of a United Kingdom real-world study of polatuzumab vedotin, bendamustine, and rituximab for relapsed/refractory DLBCL

Blood Adv. 2022 May 10;6(9):2920-2926. doi: 10.1182/bloodadvances.2021005953.
No abstract available

MeSH terms

  • Antibodies, Monoclonal
  • Bendamustine Hydrochloride / therapeutic use
  • Immunoconjugates*
  • Rituximab / adverse effects

Substances

  • Antibodies, Monoclonal
  • Immunoconjugates
  • Rituximab
  • Bendamustine Hydrochloride
  • polatuzumab vedotin